CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty ...
GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over ...
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified portfolio ...
Unknown litigation costs have cast a cloud over wide-moat GSK GSK since 2020, when the US Food and Drug Administration requested that Zantac be taken off the market. But earlier this month, GSK ...
GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. He joined GSK in 2017 and is currently Chief ...
GSK plc (NYSE:GSK) is included among the 15 Global Dividend Stocks to Diversify Your Portfolio. On December 10, HSBC analyst Rajesh Kumar raised the firm’s price target on GSK plc (NYSE:GSK) to 1,500 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results